Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Riverwater Partners Small Cap Strategy Nathan Fredrick, CFA | “IRadimed Corporation ($IRMD) is the preeminent developer of non-magnetic, MRI-compatible intravenous infusion pumps and vital sign monitors, initiated as a new portfolio holding funded from acquired proceeds. The manager is distinctly bullish, arguing that the market has handed investors an attractive entry point into the most significant multi-year product upgrade cycle in the company's history. The investment case is underpinned by high barriers to entry, strong pricing power, and an accelerating replacement cycle across an installed base of 6,400 aging pump channels. Early demand for the next-generation 3870 pump has beaten expectations, with over 70% of orders opting for the quad-stack configuration that doubles channels per site and secures a 20% price premium above $110,000 per system, bolstered by high-margin recurring disposable consumables growing over 14%. Upcoming catalysts feature doubling production capacity to over 300 units quarterly, gross margin expansion back toward historical highs by Q4, and unmodelled greenfield customer acquisitions. Downside risks involve manufacturing ramp bottlenecks and delivery delays amidst stretching order backlogs.” | BULL | Q3 2026 Oct 15, 2026 | View Pitch |
Conestoga Micro Cap Composite Derek Johnston | “IRadimed Corp. (IRMD) rose 28% after delivering record third quarter results and announcing a special cash dividend. The company delivered record third-quarter revenue and earnings, prompting management to raise full-year guidance. This strong operational performance, combined with the announcement of a special cash dividend, underscored the company's financial health and commitment to shareholder returns. We believe IRMD's niche leadership and innovative product pipeline continue to offer a compelling growth trajectory. BSD Analysis: IRadimed operates a near-monopoly in MRI-compatible patient monitoring, a niche hospitals cannot ignore. Its equipment is mission-critical, regulated, and deeply embedded in clinical workflows. Competition is minimal because the technical and regulatory barriers are brutal. Revenue can be lumpy due to hospital capex timing, but margins are exceptional. Investors overlook IRadimed because the TAM looks small on slides. In practice, niche dominance beats broad mediocrity. Expansion into adjacent MRI-safe devices adds optionality. Cash generation is strong relative to size. This is quiet monopoly economics hiding in plain sight.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Riverwater Micro Opportunities Strategy Nathan Fredrick, CFA | “IRadimed Corporation (IRMD) was our top contributor for both the quarter and the full year. The MRI-compatible medical device company rallied nearly 38% in the fourth quarter and gained approximately 80% for the year. IRMD won FDA approval for its MRI-compatible 3870 IV infusion pump in July 2025, as expected. The company estimates that it will be able to generate $50 million of 3870 revenue during 2026, in addition to its strong monitor revenue, with more growth to come in 2027. The company's accelerating revenue growth and profitability should enable the stock to continue to perform well in 2026 and beyond. IRadimed remains our largest position and a good example of accelerating growth with high returns on invested capital. BSD Analysis: IRadimed operates in a niche that sounds small until you realize hospitals can't operate MRIs safely without its equipment. Its MRI-compatible patient monitoring systems face almost no credible competition. Regulatory approvals and switching costs create a durable moat. Revenue is lumpy but margins are exceptional. Hospital capex cycles create timing risk, not demand risk. Investors ignore IRadimed because the TAM looks narrow on paper. But narrow markets with monopolistic positioning compound quietly. Expansion into adjacent MRI-safe devices adds optionality. This is niche dominance done right.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.